Janssen Launches Phase 3 Trial of First-in-Class GPRC5D/BCMA/CD3 Trispecific Antibody Ramantamig in Frontline Multiple Myeloma

▎Armstrong

On June 24, 2026, Johnson & Johnson registered the Phase III clinical trial TRILogy-7 on ClinicalTrials.gov, evaluating the combination of the GPRC5D/BCMA/CD3 trispecific antibody Ramantamig and the CD38 antibody Daratumumab as first-line treatment for multiple myeloma.

This Phase III clinical trial plans to enroll 1,000 patients with newly diagnosed multiple myeloma, using DVRd or DRd standard therapy as the positive control, and is expected to be initially completed by September 2030.

Ramantamig is the world’s first GPRC5D/BCMA/CD3 trispecific antibody. This marks the third Phase III clinical trial initiated by Johnson & Johnson, following previously launched Phase III trials for fourth-line and later treatments, as well as for second- to fourth-line treatments. With this development, Ramantamig has now covered all lines of therapy for advanced multiple myeloma.

At the ASH meeting late last year, Johnson & Johnson disclosed Phase I clinical data for ramantamig. Among 36 evaluable patients at the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86% (75% achieving ≥ very good partial response [VGPR]). In the subgroup of 27 patients who had not previously received GPRC5D- or BCMA-targeted therapies, the ORR was 100% (89% achieving ≥ VGPR).

Summary

In China, Innovent’s GPRC5D/BCMA/CD3 has entered Phase III clinical trials, while Mabworks, Simcere Pharmaceutical, Qilu Pharmaceutical, and Bendao Biologics have also advanced their GPRC5D/BCMA/CD3 candidates to the clinical stage.